Cover Image
市場調查報告書

糖原合成酵素激酶β (GSK3β) :開發中產品分析

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363579
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
糖原合成酵素激酶β (GSK3β) :開發中產品分析 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 58 Pages
簡介

本報告提供糖原合成酵素激酶β (GSK3β)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

糖原合成酵素激酶β (GSK3β)的概要

治療藥的開發

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各開發階段

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各治療範圍

糖原合成酵素激酶β (GSK3β):開發中的產品 - 各適應症

糖原合成酵素激酶β (GSK3β):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

糖原合成酵素激酶β (GSK3β):企業開發中的產品

糖原合成酵素激酶β (GSK3β):大學/機關開發中的產品

糖原合成酵素激酶β (GSK3β):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

糖原合成酵素激酶β (GSK3β)的治療藥的開發企業

  • AMO Pharma Limited
  • Angelini Group
  • Celon Pharma Sp. z o.o.
  • DiaMedica Inc.
  • HitGen LTD
  • Jeil Pharmaceutical Co., Ltd.
  • 田邊三菱製藥
  • Neurim Pharmaceuticals Ltd

藥物簡介

糖原合成酵素激酶β (GSK3β):暫停中的計劃

糖原合成酵素激酶β (GSK3β):開發中止的產品

糖原合成酵素激酶β (GSK3β):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1048TDB

Summary:

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules. It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 20 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 5 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Metabolic Disorders, Cardiovascular, Genetic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Alzheimer's Disease, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Lung Cancer, Type 2 Diabetes, Breast Cancer, Cognitive Impairment, Dyskinesia, Glioblastoma Multiforme (GBM), Hypertension, Kidney Cancer (Renal Cell Cancer), Liver Cancer, Menkes Disease (Kinky Hair Disease), Multiple Sclerosis, Myotonic Dystrophy, Neuroblastoma, Neurodegenerative Diseases, Ovarian Cancer, Retinitis Pigmentosa (Retinitis) and Tauopathies.

The latest report Glycogen Synthase Kinase 3 Beta - Pipeline Review, H2 2017, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
  • The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview
    • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • Actuate Therapeutics Inc
    • AMO Pharma Ltd
    • Angelini Group
    • DiaMedica Therapeutics Inc
    • Jeil Pharmaceutical Co Ltd
    • Mitsubishi Tanabe Pharma Corp
    • Neurim Pharmaceuticals Ltd
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles
    • 9-ING41 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DM-204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit GSK3-Beta for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IB-AD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JGK-263 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • manzamine A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neu-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit GSK3B for Ovarian Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit GSK3b for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GSK-3 Beta for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GSK-3 Beta for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GSK3B and Activate Nrf2 for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GSK3B for Amyotropic Lateral Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit GSK3B for Cardiovascular, Central Nervous System and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tideglusib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products
  • Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 25, 2017: AMO Pharma Reports Update on Positive Interim Analysis for the First Cohort of Phase IIa Congenital Myotonic Dystrophy Study
      • Jul 27, 2017: AMO Pharma Receives FDA Orphan Drug Designation for AMO-02 for Treatment of Congenital Myotonic Dystrophy
      • May 30, 2017: AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
      • Apr 03, 2017: Actuate Therapeutics' Programs Highlighted in Clinical Cancer Research
      • Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy
      • Mar 29, 2016: FDA grants 9-ING-41 an Orphan Drug Designation for treatment of glioblastoma
      • Dec 18, 2015: Actuate Therapeutics Provides Update On 9-ING4
      • Nov 19, 2015: Actuate Therapeutics Presents Data On 9-ING41 at the Society of Neuro Oncology meeting
      • Apr 20, 2015: Actuate Therapeutics Provides Update On GSK-3B at the AACR Meeting
      • Dec 03, 2012: Alzheimer's researcher reveals a protein's dual destructiveness - and therapeutic potential
      • Sep 27, 2012: DiaMedica's DM-204 Selected For Poster Presentation At 2012 American Heart Association's Scientific Conference
      • Jul 20, 2012: Noscira Presents Phase II Results Of tideglusib At Alzheimer's Association International Conference 2012
      • Jun 14, 2012: DiaMedica Announces Summary Of DM-204 Program At 72nd Annual American Diabetes Association Conference
      • Jun 01, 2012: DiaMedica's DM-204 Program Selected For Presentation At American Diabetes Association's 72nd Scientific Conference
      • Mar 22, 2012: DiaMedica Provides Update On DM-204
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Actuate Therapeutics Inc, H2 2017
  • Pipeline by AMO Pharma Ltd, H2 2017
  • Pipeline by Angelini Group, H2 2017
  • Pipeline by DiaMedica Therapeutics Inc, H2 2017
  • Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017
  • Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
  • Pipeline by Neurim Pharmaceuticals Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administrations, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top